The 24-month overall survival probability in a cohort of patients with high gene expression versus low gene expression of listed chemokines in tumor specimens was 0.2 vs. 0.35 for IL-4, 0.2 vs. 0.35 for IL-10, 0.2 vs. 0.4 for CCL2, 0.2 vs. 0.57 for GM-CSF, and 0.15 vs. 0.23 for VEGF. This evidence concerns the gene CSF2 and neoplasm.